| Ytd | 145.85% | |
| 1y | 139.43% |
| Open | 70.10 | Prev Close | 70.03 | Low | 68.87 | High | 73.90 | Mkt Cap | 28.77B |
| Vol | 6.70M | Avg Vol | 7.36M | EPS | -8.14 | P/E | N/A | Forward P/E | -17.52 |
| Beta | 1.03 | Short Ratio | 10.94 | Inst. Own | 78.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-31 | 50-d Avg | 52.14 | 200-d Avg | 40.84 | 1yr Est | 44.25 |
At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It's
On June 16, Moderna announced major news regarding one of its most highly anticipated follow-up prod
Betting against Palantir, Rocket Lab and Strategy was June's smartest move — leveraged short fun
Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines
Moderna, Inc. (NASDAQ:MRNA) shares are trading higher on Monday. This follows Friday's gain of more
A classic 'flag' pattern has formed on the chart of Moderna (MRNA). This continuation patter
Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted t
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D
Piper Sandler analyst Edward Tenthoff maintains Moderna (NASDAQ:MRNA) with a Overweight and raise
Semiconductors cratered Friday, dragging the stock market lower, while health care and software led
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon tr
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy pr
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.co
It's not just a "pandemic stock," after all.
Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Hori
Provides broad overview of Company's research and early development programs expected to continu
Provides broad overview of Company's research and early development programs expected to continue to
Moderna’s experimental flu vaccine won unanimous FDA panel backing ahead of an Aug. 5 decision.
FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026CAMBRIDGE, MA / ACCESS Ne
Moderna shares have surged nearly 30% in five days, ahead of a key FDA advisory vote on its flu vacc
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-vote-favor-modernas-flu-
Moderna flu vaccine faces a key FDA advisory panel review as analysts weigh approval odds, postmarke
Major U.S. indexes closed mixed on Tuesday, with the Dow Jones Industrial Average gaining 0.6% to 51
Financials and utilities led Wall Street higher Tuesday as oil slid toward $77 and investors brace f
Moderna expands leadership roles and commercial operations as it prepares for multiple vaccine launc
Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to support its short- and
Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk
B of A Securities analyst Dimple Gosai maintains Moderna (NASDAQ:MRNA) with a Underperform and ra
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
Moderna reports five-year melanoma trial results with Merck and expands its Ebola vaccine partnershi
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study,
Moderna, Inc. (NASDAQ:MRNA) today announced an expanded collaboration with the Coalition for Epidemi